Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07818629) titled 'A Study to Evaluate INT101 in Healthy Adults for the Prevention of Norovirus Gastroenteritis' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Single (Participant).
Primary Sponsor: InThera Inc. Korea
Condition:
Norovirus Infections
Norovirus Gastroenteritis
Intervention:
Biological: INT101 Low Dose
Biological: INT101 High Dose
Biological: INT101 Placebo (0.25 mL)
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: August 10, 2026
Target Sample Size: 30
Countries of Recruitm...